Clinical Data Guide · Last verified June 11, 2026

CagriSema Side Effects: What the Trial Data Actually Shows

By The RX Index Editorial Team — The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We are not a medical provider, and this guide is information, not medical advice. Disclosure: The RX Index may earn a commission if you start care through some links on this page. That never changes the facts we verify or what we tell you.

If you’re looking up CagriSema side effects, here’s the straight answer first: they’re mostly stomach-related — nausea, constipation, vomiting, and diarrhea — and they’re common. In the big REDEFINE 1 trial, about 8 in 10 people on CagriSema had at least one gut side effect, and nausea led the way at 55%. Now the good news buried in that scary number: most were mild to moderate, faded over time, and only about 6% of people quit because of them. The serious risks — like pancreatitis or gallbladder problems — are uncommon and mostly familiar from the wider GLP-1 class (semaglutide, tirzepatide).

Here’s the part most pages skip: you can’t actually buy CagriSema yet. It isn’t FDA approved, which means the FDA hasn’t confirmed it’s safe and effective, and there’s no official label. And the newest trial data — released June 7, 2026 at the American Diabetes Association meeting — shifts part of the picture. We’ll walk you through all of it, plain and simple, including what to do if you wanted CagriSema and just found out you can’t get it.

CagriSema side effects at a glance

What is CagriSema, and why do people worry about its side effects?

CagriSema is an investigational weekly injection from Novo Nordisk that puts two medicines in one shot: semaglutide (the same active medicine in Ozempic and Wegovy, a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog — a lab-made version of amylin, one of the hormones your body uses to feel full). Pairing two appetite signals is exactly why it produced some of the strongest weight loss ever seen in a trial. It’s also why the side-effect question gets complicated — two mechanisms means two chances for side effects, especially in the gut. More on what CagriSema is →

Here’s where CagriSema stands today. In REDEFINE 1 (people with obesity, no diabetes), it produced about 20.4% average body weight loss over 68 weeks counting everyone in the trial — even people who stopped early — or 22.7% when measured only among people who stayed on it without adding other weight-loss treatments (NEJM, 2025). That’s powerful. But powerful isn’t the same as “easiest to tolerate” — and in a head-to-head trial against Zepbound (tirzepatide), CagriSema lost on both weight loss and side effects. That context belongs in any honest side-effect summary.

What are the most common CagriSema side effects?

The most common CagriSema side effects are gastrointestinal, meaning they affect your stomach and gut: nausea, constipation, vomiting, and diarrhea. In REDEFINE 1, gut side effects happened in 79.6% of people on CagriSema versus 39.9% on placebo, and most were mild to moderate and temporary (NEJM, 2025).

Here’s the real breakdown from the trial. We use the actual published rates — not the rounded-down “40–45% nausea” figure you’ll see on some sites, which understates it.

Source: REDEFINE 1, published in the New England Journal of Medicine (2025); rates reported by Novo Nordisk. The trial ran 68 weeks in 3,417 adults with obesity or overweight and no type 2 diabetes.

What “mild to moderate” really means

“Mild to moderate” is medical language, and it’s easy to misread. It does not mean pleasant. It means the side effect usually didn’t reach the trial’s “severe” bar — not that you won’t notice it. Plenty of people find nausea or constipation genuinely annoying for a few days. It’s also worth remembering that trial participants get checked on closely and coached through dose changes. Real life after a launch is often less hand-held, so the day-to-day experience can feel different from what the trial numbers suggest.

How long do CagriSema side effects last, and when do they hit hardest?

In the trials, CagriSema’s side effects were mostly temporary, and they tended to be worst when the dose stepped up — easing for many people once they settled onto a steady maintenance dose. That timing is the single most useful thing to understand, because it tells you when to expect the rough patches.

The everyday playbook clinicians lean on is simple: step up the dose slowly, eat smaller and lower-fat meals, drink plenty of water, and add fiber for constipation. It’s the standard approach for GLP-1 tolerability — and in REDEFINE 1, only 5.9% of people on CagriSema stopped because of side effects. None of this replaces your own prescriber’s guidance. But it’s the difference-maker people wish they’d known on day one.

What serious CagriSema risks should you ask a doctor about?

Serious CagriSema side effects are uncommon, but a few are worth knowing. Because CagriSema is still investigational, it doesn’t have a final FDA label yet — so the official U.S. warnings aren’t written. The serious risks worth raising with a clinician come from the semaglutide half of the drug and the wider GLP-1 class: pancreatitis (an inflamed pancreas), gallbladder problems, dehydration that can strain the kidneys, low blood sugar if you take certain diabetes medicines, a family history of a rare thyroid tumor type, and serious allergic reactions.

Here’s the honest picture from the research. In the large semaglutide heart-health trial (SELECT), serious problems involving the pancreas, kidneys, or cancer were not more common than with placebo, though gallbladder issues were somewhat more common with semaglutide (NEJM). CagriSema’s own trials described serious events as uncommon and in line with this class. But the exact rates and the official “do not use” rules will be set by the FDA label — and that doesn’t exist yet.

The most useful thing we can give you isn’t a scary list — it’s a clear sense of what to do if a symptom shows up. Use this as a conversation starter with a clinician, not a diagnosis.

General GLP-1 safety context above is drawn from the FDA-approved Wegovy (semaglutide) prescribing and safety information, since CagriSema shares that ingredient.

June 2026 update: what the new REIMAGINE diabetes trials add

On June 7, 2026, Novo Nordisk released a fresh batch of safety data from its REIMAGINE program — three phase 3 trials testing CagriSema in adults with type 2 diabetes. The headline for side effects: the same pattern held. Gut side effects were again the most common, mostly mild to moderate, and the share of people who quit over side effects ran from about 3% to 8.5%, right in line with other GLP-1 medicines (Novo Nordisk; published in The Lancet and Lancet Diabetes & Endocrinology).

This matters for a simple reason: it’s the newest data on the table, and most CagriSema pages were written before it existed.

Source: Novo Nordisk, June 7, 2026; published in The Lancet and Lancet Diabetes & Endocrinology.

Two honest takeaways. First, the gut side-effect rates in these diabetes trials (53–67%) came in a bit lower than the 79.6% seen in the REDEFINE 1 obesity trial — but the ranking never changes: stomach side effects lead, and they’re usually manageable. Second, the quit rates stayed low, which is the number that matters most for real-world tolerability. People generally stuck with it.

Are CagriSema’s side effects worse than Wegovy or Zepbound?

Short version: CagriSema does not look gentler than Wegovy, and on the numbers it runs higher on nausea than Zepbound. That makes sense — CagriSema contains semaglutide (Wegovy’s ingredient) and adds a second medicine on top. Just remember these are cross-trial comparisons, not head-to-head, so treat them as rough context.

Sources: CagriSema — REDEFINE 1 (NEJM/Novo Nordisk). Wegovy and Zepbound — each drug’s FDA prescribing information.

Here’s the honest part most affiliate pages won’t tell you. If your top priority is the lowest possible chance of nausea, CagriSema probably isn’t the drug to wait for — Zepbound had clearly lower gut side-effect rates in its trials. And in REDEFINE 4, the one trial that put them head-to-head, CagriSema produced less weight loss than tirzepatide (roughly 23% versus about 25.5% over 84 weeks), so it didn’t win that matchup either.

So why would anyone want it? Because if you’re after the strongest appetite control from two mechanisms working together, that extra gut burden is the exact trade-off you’d be signing up for. There’s no free lunch — more power, a bit more stomach. And here’s the thing: if the nausea risk is a dealbreaker for you, you don’t have to wait around for CagriSema at all. There are proven, FDA-approved options you can start now, and we’ll point you to the right fit for your situation in a moment.

Is CagriSema FDA approved, and can you get it yet?

No. CagriSema is not FDA approved and not available by prescription in the United States as of June 11, 2026. Novo Nordisk filed its application with the FDA in December 2025, and the company says a decision is expected in Q4 2026 (Novo Nordisk, June 2026). Until then, no clinic, pharmacy, or telehealth service can legally prescribe or sell it outside of a clinical trial. Track the FDA approval status →

• An FDA decision is not the same as showing up at your pharmacy. Even if it’s approved late in 2026, the actual launch, supply, and pricing usually lag behind.
• Approved is not the same as covered. Insurance coverage can take many more months to sort out.
• What we still don’t know: the final label, the official warnings and “do not use” rules, the U.S. price, the launch date, insurance coverage, and how it behaves in the real world outside a trial.

How much will CagriSema cost?

There is no official U.S. CagriSema price yet, because it isn’t approved or launched. Any website quoting a current CagriSema price is either guessing, describing an unapproved product, or selling something that is not FDA-approved CagriSema. Until Novo Nordisk sets a price after approval, the honest answer is: unknown.

Can you join a CagriSema clinical trial?

Before approval, the only legitimate way to access CagriSema is through a clinical trial. You can search ClinicalTrials.gov for active CagriSema or cagrilintide–semaglutide studies, or ask your clinician whether any are enrolling near you. One important line: a clinical trial is run by a research site with oversight and informed consent — it is not the same as a website selling “research-use” peptides, and you should never treat the two as interchangeable.

Can you buy “compounded CagriSema” or “research” cagrilintide?

No — and this is the most important safety point on the page. The FDA has stated that cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition (FDA). In plain terms: there is no legal, legitimate “compounded CagriSema.” The FDA also warns that illegally marketed GLP-1 products may be counterfeit and may contain the wrong ingredients, harmful ingredients, too little, too much, or no active medicine at all. See our guide on compounded vs. brand-name GLP-1 medicines →

If you see any of these claims, treat them as a stop sign:

Trying to buy CagriSema early isn’t getting ahead of the curve. It’s stepping outside the safety system that’s there to protect you — with a drug whose real-world risks aren’t even fully mapped yet.

Should you wait for CagriSema, or start a GLP-1 now?

It depends on what you want and when. If you want treatment soon, CagriSema isn’t a real option yet — it’s not approved or legally available. If you specifically want the amylin-plus-GLP-1 combo and you’re happy to wait, tracking the FDA decision makes sense. If you want to start in the next month or two, the smart move is to compare today’s FDA-approved options with a licensed clinician.

Find yourself in this table:

For most people landing here, the honest best move is to stop searching and get a plan. You’ve already done the hard part — the research.

Who might not be a good fit for CagriSema (if it’s approved)?

Because CagriSema has no final FDA label yet, no honest page can hand you a complete “who shouldn’t take it” list. What we can do is flag the groups who should raise this with a clinician before considering any GLP-1 medicine, based on the semaglutide ingredient and the drug class. Bring these up at your visit:

• Personal or family history of medullary thyroid cancer, or MEN2
• Pregnant, breastfeeding, or trying to conceive
• A history of pancreatitis or gallbladder disease
• Severe stomach problems, like gastroparesis (slow stomach emptying)
• Kidney disease or a high risk of dehydration
• Type 2 diabetes treated with insulin or a sulfonylurea (low blood sugar risk)
• A surgery or procedure with anesthesia coming up (GLP-1 drugs slow stomach emptying)
• A past severe allergic reaction to semaglutide or similar medicines

This isn’t a list of CagriSema’s official bans — those don’t exist yet. It’s a list of conversations worth having early.

What real people say about CagriSema side effects

There’s no way to share verified customer reviews of CagriSema, because it isn’t on the market — the only people taking it are in clinical trials. So if you come across a trial participant sharing their experience online, treat it as exactly that: one person’s story, not proof of how it’ll go for you. (In a blinded trial, they may not even know whether they got the real drug or a placebo.) The worries that come up most often are the familiar GLP-1 ones — nausea around dose changes, constipation, and a low-energy day after the weekly shot.

If the numbers above made you uneasy, that’s a normal reaction, and you’re not alone. The answer isn’t to white-knuckle it or chase a gray-market version. It’s to get a real plan with a real clinician.

How we researched and verified this guide

We built this guide from primary and high-authority sources, not by rewriting other websites. Where a number wasn’t in a public source, we flagged it instead of guessing.

Sources we used:

• Novo Nordisk / NEJM — REDEFINE 1 and REDEFINE 2 results (side-effect and discontinuation rates).
• Novo Nordisk / The Lancet — June 2026 REIMAGINE 1–3 results (diabetes-trial side effects and discontinuations).
• U.S. FDA — statement that cagrilintide cannot be used in compounding; warnings about illegally marketed GLP-1 products.
• Wegovy (semaglutide) FDA prescribing information — shared class-level risks and side-effect rates.
• Zepbound (tirzepatide) FDA prescribing information — for cross-trial comparison context.
• NEJM SELECT trial — semaglutide serious-event safety context.

What we verified:

The REDEFINE 1 nausea/constipation/vomiting and quit rates; the June 2026 REIMAGINE side-effect and discontinuation numbers; the Wegovy and Zepbound label rates; CagriSema’s current “not approved” status and Q4 2026 decision timing; and the FDA’s compounding restriction.

What we couldn’t verify yet:

The exact diarrhea and abdominal-pain rates, the precise serious-event rates, the final FDA label and warnings, the U.S. price, the launch date, and long-term real-world safety.

Last verified: June 11, 2026. Next review: within 24 hours of any FDA action on CagriSema, and monthly until then.

Frequently asked questions about CagriSema side effects

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This guide is for information only and is not medical advice. Always talk with a licensed clinician about your own health.